Chemours (NYSE: CC) shares tumbled 10.2% after the chemical manufacturer reported fourth-quarter earnings that fell short of Wall Street expectations. The company posted adjusted earnings per share of $0.05, missing the $0.07 consensus estimate, while revenue declined 2% year over year to $1.3 billion.

Management attributed the miss to cyclical weakness in the Advanced Performance Materials (APM) segment and a sizable non-cash inventory charge that pressured margins. The company recorded a net loss of $47 million, or $0.31 per diluted share, compared with a $11 million loss in the prior-year quarter. Adjusted EBITDA declined to $128 million from $168 million a year earlier.

The Thermal & Specialized Solutions segment provided a bright spot, delivering record fourth-quarter growth with 37% year-over-year growth in Opteon™ Refrigerants. However, weaker demand in cyclically sensitive end markets impacted both Titanium Technologies and APM segments. The company implemented a global TiO2 price increase effective December 1, 2025, and announced the sale of its former Kuan Yin TiO2 site for approximately $300 million in net proceeds.

For full-year 2025, Chemours reported net sales of $5.8 billion, flat year over year, but recorded a net loss of $386 million, or $2.57 per share, primarily due to litigation-related charges. the company expects 2026 consolidated net sales growth of 3% to 5% and adjusted EBITDA between $800 million and $900 million.